Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. Show more

Location: 9920 Pacific Heights Boulevard, San Diego, CA, 92121, United States | Website: https://www.vikingtherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

2.976B

52 Wk Range

$18.92 - $81.73

Previous Close

$26.50

Open

$26.35

Volume

3,691,110

Day Range

$25.80 - $27.52

Enterprise Value

2.125B

Cash

851.9M

Avg Qtr Burn

-33.5M

Insider Ownership

2.12%

Institutional Own.

70.04%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.